Pediatric Cancer

Sujith Baliga; Torunn I Yock

doi:10.1016/j.hoc.2019.08.021

Pediatric Cancer

Hematol Oncol Clin North Am. 2020 Feb;34(1):143-159. doi: 10.1016/j.hoc.2019.08.021. Epub 2019 Oct 31.

Authors

Sujith Baliga¹, Torunn I Yock²

Affiliations

¹ Department of Radiation Oncology, Massachusetts General Hospital/Harvard Medical School, Francis H. Burr Proton Therapy Center, 30 Fruit Street, Boston, MA 02114, USA.
² Francis H. Burr Proton Therapy Center, 30 Fruit Street, Boston, MA 02114, USA; Department of Radiation Oncology, Massachusetts General Hospital/Harvard Medical School, 55 Fruit Street, Boston, MA 02114, USA. Electronic address: tyock@partners.org.

PMID: 31739941
DOI: 10.1016/j.hoc.2019.08.021

Abstract

In pediatric brain tumors, the intensification of chemotherapy has allowed for a reduction in radiotherapy (RT) volume to an involved field approach, particularly in patients with medulloblastoma. For patients with low-grade gliomas, the trend has remained to delay RT with chemotherapy; however, when RT is used, typically smaller clinical target volume margins are used. For patients with extracranial tumors, intensive chemotherapy to address systemic disease with local control is considered standard. Proton beam therapy shows significant promise in addressing both short-term and long-term toxicities in both central nervous system (CNS) and non-CNS pediatric tumors.

Keywords: Pediatric cancer; Proton beam therapy; Survivorship.

Publication types

Review

MeSH terms

Adolescent
Brain Neoplasms* / mortality
Brain Neoplasms* / therapy
Child
Child, Preschool
Disease-Free Survival
Female
Humans
Infant
Infant, Newborn
Leukemia* / mortality
Leukemia* / therapy
Lymphoma* / mortality
Lymphoma* / therapy
Male
Survival Rate